spacer
home > ebr > summer 2003 > the future of vaccines
PUBLICATIONS
European Biopharmaceutical Review

The Future of Vaccines

Estimated at about $6 billion annually, the current worldwide market for vaccines centres around a list of old enemies such as tuberculosis, typhoid, cholera, tetanus, diphtheria, rabies, smallpox, yellow fever and polio. Newer vaccines have been created for chickenpox, Hepatitis B and A, influenza and pneumonia. Today, with the power of genomics, proteomics and systems biology at our fingertips, we've entered into what many believe will be a golden age for prophylactic approaches. Enter the era of 'super vaccines' -vaccines that will mitigate everything from herpes, to cancers and even AIDS. Some of them will be tailor-made to fit the individual's genetic profile.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By G Steven Burrill, CEO of Burrill & Company

G Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM).

Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.

spacer
G Steven Burrill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>

White Papers

Case Study: Getting the Clients Trust - Oncology Program

Cmed Clinical Services

Five years ago, a biopharmaceutical company chose Cmed to conduct a phase II oncology study. Cmeds performance of the study and the good relationship established with the Client led Cmed to be awarded a second oncology trial which a couple of years ago was followed by a third, fourth and fifth.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement